- Conditions
- Cancer
- Interventions
- CGC-11047 and gemcitabine, CGC-11047 and docetaxel, CGC-11047 and bevacizumab, CGC-11047 and erlotinib, CGC-11047 and cisplatin, CGC-11047 and 5-flurouracil / leucovorin, CGC-11047 and sunitinib
- Drug
- Lead sponsor
- Progen Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 12
- States / cities
- Denver, Colorado • Ocoee, Florida • Indianapolis, Indiana + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 361–384
of 639
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Locally Advanced Pancreatic Cancer, Borderline Pancreatic Inoperable Cancer, Pancreatic Cancer
- Interventions
- Folfirinox, Gemcitabine nab-Paclitaxel
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Colorectal Adenocarcinoma
- Interventions
- Bevacizumab, Oxaliplatin, Leucovorin Calcium, Fluorouracil, Irinotecan Hydrochloride, Irinotecan, Cholecalciferol, Quality-of-Life Assessment, Questionnaire Administration
- Drug · Dietary Supplement · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 455 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1027
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 676 more
- Conditions
- Gastric Cancer
- Interventions
- Placebo, Onartuzumab (MetMAb), Oxaliplatin, Folinic acid, Levofolinic acid, 5-Fluorouracil
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 18
- States / cities
- Denver, Colorado • New Haven, Connecticut • Fort Myers, Florida + 15 more
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Cancer of the Pancreas
- Interventions
- Zunsemetinib, mFOLFIRINOX
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer
- Interventions
- oxaliplatin, irinotecan, leucovorin, 5-fluorouracil, capecitabine, radiation, surgery, gemcitabine
- Drug · Radiation · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 14
- States / cities
- La Jolla, California • Chicago, Illinois • Evanston, Illinois + 11 more
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- ABT-888, mFOLFOX-6
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2023
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Peritoneal Cavity Cancer
- Interventions
- fluorouracil, leucovorin calcium, oxaliplatin, cytoreductive surgery
- Drug · Procedure
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin), Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 5
- States / cities
- Wichita, Kansas • Metairie, Louisiana • Brockton, Massachusetts + 2 more
- Conditions
- Advanced Solid Tumors
- Interventions
- Dalutrafusp alfa, mFOLFOX6 Regimen
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Boston, Massachusetts • Dallas, Texas + 1 more
- Conditions
- Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Rectum, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer
- Interventions
- bevacizumab, oxaliplatin, leucovorin calcium, fluorouracil, laboratory biomarker analysis
- Biological · Drug · Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Adenocarcinoma Esophagus, Adenocarcinoma of the Gastroesophageal Junction
- Interventions
- Sequential FLOT followed by chemoradiation
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 7
- States / cities
- Aurora, Colorado • Colorado Springs, Colorado • Fort Collins, Colorado + 2 more
- Conditions
- Colorectal Cancer
- Interventions
- Regorafenib, 5-FU, Leucovorin
- Drug
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Gastroesophageal Cancer, Gastric Cancer
- Interventions
- FOLFOX, bevacizumab
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 2
- States / cities
- Hamden, Connecticut • New Haven, Connecticut
- Conditions
- Colon Cancer
- Interventions
- recombinant nematode anticoagulant protein c2 (rNAPc2)
- Drug
- Lead sponsor
- ARCA Biopharma, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Colorectal Cancer, Metastatic Colorectal Cancer
- Interventions
- Onvansertib, FOLFIRI, Bevacizumab
- Drug
- Lead sponsor
- Cardiff Oncology
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 24 more
- Conditions
- Peritoneal Mesothelioma, Peritoneal Carcinomatosis, Ovarian Cancer, Gastrointestinal Cancer, Appendiceal Cancer, Atypical Mesothelial Proliferation, Colorectal Cancer
- Interventions
- Sodium Thiosulfate, 5-Fluorouracil, Oxaliplatin, Doxorubicin, Hyperthermic Intraperitonial Chemotherapy, Cisplatin, Mitomycin C
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2034
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- Interventions
- Subcutaneous Tislelizumab, Intravenous Tislelizumab, Cisplatin, Leucovorin, 5-fluorouracil (5-FU), Oxaliplatin, Capecitabine
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 351 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 19
- States / cities
- Chandler, Arizona • Los Alamitos, California • Colorado Springs, Colorado + 16 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- HAI with FOLFOX
- Drug
- Lead sponsor
- Western Regional Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Goodyear, Arizona
- Conditions
- Borderline Resectable Pancreatic Ductal Adenocarcinoma
- Interventions
- Biospecimen Collection, Computed Tomography, Fluorouracil, Irinotecan Sucrosofate, Leucovorin Calcium, Oxaliplatin, Surgical Procedure
- Procedure · Drug
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Pancreatic Cancer, Cachexia, Weight Loss
- Interventions
- Xilonix plus Onivyde and 5FU
- Drug
- Lead sponsor
- Andrew Hendifar, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Pharmacokinetics of Zolbetuximab, Gastric Cancer, Gastro-esophageal Junction (GEJ) Cancer, Pharmacokinetics of Oxaliplatin, Pharmacokinetics of Fluorouracil Bolus (5-FU)
- Interventions
- zolbetuximab, oxaliplatin, leucovorin, fluorouracil, Pembrolizumab, folinic acid, nivolumab, Docetaxel
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Santa Monica, California • Chicago, Illinois + 2 more
- Conditions
- 2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer
- Interventions
- GVAX Pancreas Vaccine, CRS-207, Chemotherapy, cyclophosphamide
- Biological · Drug
- Lead sponsor
- Aduro Biotech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 303 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 20
- States / cities
- Scottsdale, Arizona • La Jolla, California • San Francisco, California + 16 more
- Conditions
- Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms
- Interventions
- Vatalanib
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 145
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 123 more